Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G M Mol

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Pharmacoepidemiology and Drug Safety|January 8, 2014
Critically reviewing impact of regulatory actions, not just FDA'sPeter G M Mol
Nederlands Tijdschrift Voor Geneeskunde|May 22, 2014
[The new pharmacovigilance legislation in practice]André W Broekmans, Peter G M Mol
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 3, 2014
GFR decline as an end point for clinical trials in CKD: a view from EuropePeter G M Mol, Romaldas Maciulaitis, Thorsten Vetter
Lung Cancer (Amsterdam, Netherlands)|March 5, 2025
Reassessing pembrolizumab dosing in NSCLC for methodological and clinical accuracy - Author's replyGeeske F Grit, Peter G M Mol, Doranne Hilarius
Current Opinion in Nephrology and Hypertension|September 4, 2015
Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scoresBauke Schievink, Peter G M Mol, Hiddo J Lambers Heerspink
Lancet (London, England)|July 6, 2017
A personalised or procrustean approach to treating hypertension?Genevieve M Gabb, Peter G M Mol, Leonard F Arnolda
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 26, 2025
Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024Diogo Almeida, Diana Mandslay, Peter G M Mol, et al.
Plos One|December 15, 2023
A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language modelErik Bergman, Anna Maria Gerdina Pasmooij, Peter G M Mol, et al.
British Journal of Clinical Pharmacology|September 2, 2018
Healthcare professionals' level of medication knowledge in Africa: a systematic reviewDerbew Fikadu Berhe, Katja Taxis, Flora M Haaijer-Ruskamp, et al.
Pharmacoepidemiology and Drug Safety|March 23, 2025
Mixed Impact of Direct Healthcare Professional Communications When Considering Proximal Outcomes and the Targeted Population: A Systematic ReviewEsther de Vries, Petra Denig, Taco B M Monster, et al.
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Pharmacoepidemiology and Drug Safety|January 8, 2014
Critically reviewing impact of regulatory actions, not just FDA'sPeter G M Mol
Nederlands Tijdschrift Voor Geneeskunde|May 22, 2014
[The new pharmacovigilance legislation in practice]André W Broekmans, Peter G M Mol
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 3, 2014
GFR decline as an end point for clinical trials in CKD: a view from EuropePeter G M Mol, Romaldas Maciulaitis, Thorsten Vetter
Lung Cancer (Amsterdam, Netherlands)|March 5, 2025
Reassessing pembrolizumab dosing in NSCLC for methodological and clinical accuracy - Author's replyGeeske F Grit, Peter G M Mol, Doranne Hilarius
Current Opinion in Nephrology and Hypertension|September 4, 2015
Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scoresBauke Schievink, Peter G M Mol, Hiddo J Lambers Heerspink
Lancet (London, England)|July 6, 2017
A personalised or procrustean approach to treating hypertension?Genevieve M Gabb, Peter G M Mol, Leonard F Arnolda
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 26, 2025
Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024Diogo Almeida, Diana Mandslay, Peter G M Mol, et al.
Plos One|December 15, 2023
A full-document analysis of the semantic relation between European Public Assessment Reports and EMA guidelines using a BERT language modelErik Bergman, Anna Maria Gerdina Pasmooij, Peter G M Mol, et al.
British Journal of Clinical Pharmacology|September 2, 2018
Healthcare professionals' level of medication knowledge in Africa: a systematic reviewDerbew Fikadu Berhe, Katja Taxis, Flora M Haaijer-Ruskamp, et al.
Pharmacoepidemiology and Drug Safety|March 23, 2025
Mixed Impact of Direct Healthcare Professional Communications When Considering Proximal Outcomes and the Targeted Population: A Systematic ReviewEsther de Vries, Petra Denig, Taco B M Monster, et al.
Pageof 12